ProfileGDS4814 / ILMN_1721354
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 20% 1% 1% 5% 1% 21% 14% 4% 10% 10% 2% 5% 3% 1% 25% 9% 1% 2% 3% 9% 2% 16% 9% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)43.597420
GSM780708Untreated after 4 days (C2_1)32.71361
GSM780709Untreated after 4 days (C3_1)36.72161
GSM780719Untreated after 4 days (C1_2)39.23045
GSM780720Untreated after 4 days (C2_2)35.35641
GSM780721Untreated after 4 days (C3_2)43.729421
GSM780710Trastuzumab treated after 4 days (T1_1)42.267914
GSM780711Trastuzumab treated after 4 days (T2_1)39.03454
GSM780712Trastuzumab treated after 4 days (T3_1)41.10810
GSM780722Trastuzumab treated after 4 days (T1_2)41.091210
GSM780723Trastuzumab treated after 4 days (T2_2)37.60442
GSM780724Trastuzumab treated after 4 days (T3_2)39.48785
GSM780713Pertuzumab treated after 4 days (P1_1)38.46773
GSM780714Pertuzumab treated after 4 days (P2_1)36.73171
GSM780715Pertuzumab treated after 4 days (P3_1)44.530225
GSM780725Pertuzumab treated after 4 days (P1_2)40.88219
GSM780726Pertuzumab treated after 4 days (P2_2)36.82611
GSM780727Pertuzumab treated after 4 days (P3_2)37.23632
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)38.44333
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)40.82419
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)37.16462
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)42.706216
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)40.75919